Appendix I.
Study data.
| Trial | Indication | Dose (mg) | Duration | Sample size | MI | Stroke | MVE | CHF | HT |
|---|---|---|---|---|---|---|---|---|---|
| SUCCESS-I [Singh et al. 2006] | OA | C200 | 3 months | 4393 | 8 | 1 | 1 | - | - |
| C400 | 3 months | 4407 | 2 | 4 | 2 | - | - | ||
| Nap 1000 | 3 months | 4394 | 1 | 6 | 2 | - | - | ||
| Dic100 | |||||||||
| EDGE [Baraf et al. 2007] | OA | E90 | 9.3 months | 3593 | 19 | 6 | 14 | 5 | 210 |
| Dic150 | 8.9 months | 3518 | 13 | 10 | 17 | 4 | 95 | ||
| EDGE II [Krueger et al. 2008] | RA | E90 | 19.3 months | 2032 | 14 | 8 | 21 | 16 | 240 |
| Dic150 | 19.1 months | 2054 | 22 | 12 | 15 | 10 | 197 | ||
| MEDAL 2009 [Coombe et al. 2009] | OA/RA | E60 | 20.8 months | 11787 | - | - | 394 | - | - |
| E90 | 20.8 months | - | - | - | - | ||||
| Dic150 | 20.8 months | 11717 | - | - | 363 | - | - | ||
| VIGOR [Bombardier et al. 2000] | RA | R50 | 9 months | 4047 | 16 | - | - | - | - |
| Nap1000 | 9 months | 4029 | 4 | - | - | - | - | ||
| ADVANTAGE [Lisse et al. 2003] | OA | R25 | 3 months | 2785 | 5 | 1 | 14 | - | - |
| Nap1000 | 3 months | 2772 | 1 | 6 | 7 | - | - | ||
| Geusens et al. [2002] | RA | R25 | 3 months | 306 | - | - | - | - | 14 |
| Nap1000 | 3 months | 142 | - | - | - | - | 4 | ||
| Geusens et al. [2002] | RA | R50 | 3 months | 286 | - | - | - | - | 14 |
| Nap1000 | 3 months | 142 | - | - | - | - | 0 | ||
| CONDOR [Chan et al. 2010] | OA/RA | C200Dic150 | 6 months6 months | 22382246 | 3 2 | 3 3 | 8 1 | – | – |
| Cannon et al. [2000] | OA | R12.5 | 12 months | 259 | 1 | - | - | 1 | - |
| R25 | 12 months | 257 | 1 | - | - | 0 | - | ||
| Dic150 | 12 months | 268 | 2 | - | - | 3 | - | ||
| Collantes et al. [2002] | RA | E90 | 3 months | 353 | - | - | - | 0 | 12 |
| Nap1000 | 3 months | 181 | - | - | - | 0 | 5 | ||
| P | 3 months | 357 | - | - | - | 0 | 5 | ||
| Weisenhutter et al. [2005] | OA | E30 | 3 months | 214 | - | - | - | 0 | 4 |
| Ib2400 | 3 months | 210 | - | - | - | 0 | 8 | ||
| P | 3 months | 104 | - | - | - | 0 | 1 | ||
| Saag et al. [2000] | OA | R12.5 | 12 months | 231 | - | - | 3 | - | - |
| R25 | 12 months | 232 | - | - | 4 | - | - | ||
| Dic150 | 12 months | 230 | - | - | 3 | - | - | ||
| Saag et al. [2000] | OA | R12.5 | 6 weeks | 219 | - | - | 1 | - | - |
| R25 | 6 weeks | 227 | - | - | 2 | - | - | ||
| Ib2400 | 6 weeks | 221 | - | - | 0 | - | - | ||
| Zacher et al. [2003] | OA | E60 | 6 weeks | 256 | - | - | 0 | 0 | 8 |
| Dic150 | 6 weeks | 260 | - | - | 1 | 1 | 9 | ||
| McKenna et al. [2001] | OA | C200 | 6 weeks | 201 | - | - | 0 | - | - |
| D150 | 6 weeks | 199 | - | - | 2 | - | - | ||
| Matsumoto et al. [2002] | RA | E90 | 12 weeks | 323 | - | - | - | - | 7 |
| Nap1000 | 12 weeks | 170 | - | - | - | - | 3 | ||
| CAESAR [Dahlberg et al. 2009] | OA | C200 | 52 weeks | 458 | 4 | 1 | 3 | - | - |
| Dic150 | 52 weeks | 458 | 6 | 5 | 2 | - | - | ||
| Emery et al. [1999] | RA | C200 | 6 weeks | 326 | 0 | 0 | 0 | 0 | 4 |
| Dic75 | 6 weeks | 329 | 0 | 0 | 0 | 0 | 5 | ||
| Bingham et al. [2007] | OA | E30 | 26 weeks | 231 | - | - | - | - | 15 |
| C200 | 26 weeks | 241 | - | - | - | - | 9 | ||
| P | 26 weeks | 127 | - | - | - | - | 0 | ||
| Schnitzer et al. [2005] | OA | R25 | 6 weeks | 104 | 0 | 0 | 0 | - | - |
| P | 6 weeks | 107 | 1 | 0 | 1 | - | - | ||
| Nap1000 | 6 weeks | 121 | 1 | 0 | 1 | - | - |
C, celecoxib; CHF, congestive heart failure; Dic, diclofenac; E, etoricoxib; HT, hypertension; Ib, ibuprofen; MI, myocardial infarction; MVE, major vascular events; Nap, naproxen; OA, osteoarthritis; R, rofecoxib; RA, rheumatoid arthritis.